Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04568356 · ClinicalTrials.gov registry record · NA
A Clinical Evaluation of COVID-19 Rapid Point of Care Antigen Tests
A NA study of SARS-CoV-2, sponsored by E25Bio.
- Completed
- Registry status
- NA
- Development phase
- 200
- Enrollment target
- 3
- Study locations
NCT04568356 is a NA study of SARS-CoV-2 that has completed, run by E25Bio. The registered enrollment target is 200 participants, below the 3,763-participant average among 28 other SARS-CoV-2 trials with a reported enrollment target (95% lower). The trial reports 3 study locations across 1 state.
The verdict
NCT04568356, a NA study of SARS-CoV-2, has completed, sponsored by E25Bio.
- COMPLETED
- Registry status
- NA
- Development phase
- 200 participants
- Enrollment target
- 3
- Study locations
Study Summary
The current standard of care for diagnosis of Severe Acute Respiratory Syndrome associated Coronavirus -2 (SARS-CoV-2 ) infection involves sample collection to be prepared and measured via real time-polymerase chain reaction (RT-PCR). This process is often time consuming depending on the level of automation within the laboratory processing the samples. In many cases, sample turn-around times can take hours to several days. A rapid assay that does not require the sophisticated laboratory equipment and techniques could provide a significant advantage to the way practitioners screen and ultimately treat patients. Moreover, the collection of samples from the nasal nares should prove useful and less invasive. The study aims to validate the use of nasal swabs and also to validate the antigen test using nasal swabs.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Direct Antigen Tests for COVID-19
Study Locations (3)
Florida
- JFK Medical Center - Miami
- Kendall Regional - Miami
- Aventura Hospital and Medical Center - Miami
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2020-04-24 |
| Est. Completion | 2020-09-24 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04568356
The ClinicalTrials.gov registry entry for NCT04568356 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,763-participant average among 28 other SARS-CoV-2 trials with a reported enrollment target (95% lower). The listed sponsor is E25Bio, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with SARS-CoV-2 appearing as the primary indexed condition, and to 1 intervention - of which Direct Antigen Tests for COVID-19 is the first listed.
NCT04568356 reports 3 study locations spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT04568356 about?
NCT04568356 is a clinical study titled "A Clinical Evaluation of COVID-19 Rapid Point of Care Antigen Tests". The current standard of care for diagnosis of Severe Acute Respiratory Syndrome associated Coronavirus -2 (SARS-CoV-2 ) infection involves sample collection to be prepared and measured via real time-polymerase chain reaction (RT-PCR). This process is often time consuming depending on the level of au...
What is the current status of trial NCT04568356?
This trial is currently completed. It is a NA study. The enrollment target is 200 participants. The study started on 2020-04-24. Estimated completion is 2020-09-24.
What conditions does trial NCT04568356 study?
This clinical trial studies the following conditions: SARS-CoV-2.
What interventions are being tested in trial NCT04568356?
The interventions under investigation include: Direct Antigen Tests for COVID-19 (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT04568356?
This trial is sponsored by E25Bio, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04568356 being conducted?
This trial has 3 study locations across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for SARS-CoV-2
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Improving the Collaborative Health of Minority COVID-19 Survivor and Carepartner Dyads
RECRUITING · NA
-
NOWDx Test for the Detection of Antibodies to COVID-19
COMPLETED · NA
-
Seroprevalence of SARS CoV 2 Antibodies in Previously Undiagnosed Healthcare Workers
COMPLETED · NA
-
A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Vaccine Formulations
RECRUITING · Phase 4
-
A Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participants 50 to 64 Years of Age Without High-Risk Conditions for Severe Coronavirus Disease 2019 (COVID-19)
RECRUITING · Phase 4
-
Determinants of SARS (Severe Acute Respiratory Syndrome)-COV2 (COVID-19) Persistence After Convalescence
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.